Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Lawson Health Research Institute Eli Lilly and Company Regional Mental Health Care, London |
---|---|
Information provided by: | Lawson Health Research Institute |
ClinicalTrials.gov Identifier: | NCT00377117 |
The purpose of this study is to learn more about the relationship between serious mental illness and the detection and management of diabetes and pre-diabetic conditions. Patients who have been diagnosed with schizophrenia are at an increased risk for developing diabetes and pre-diabetic conditions such as impaired glucose tolerance and impaired fasting glucose. In addition, novel antipsychotics have also been linked to impaired glucose metabolism and increased incidence of diabetes. The medical management of these patients may be difficult ot achieve through standard family practice. The objectives of this project are to: screen a sample of this high-risk population using an Oral Glucose Tolerance Test (OGTT), and to provide multidisciplinary team support to those identified as having diabetes or a pre-diabetic condition.
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus Schizophrenia Psychotic Disorders |
Procedure: Management Procedure: Screening |
Phase I Phase II |
Study Type: | Observational |
Study Design: | Screening, Longitudinal, Defined Population, Retrospective/Prospective Study |
Official Title: | Diabetes Screening, Risk Management, and Disease Management in a High-Risk Mental Health Population. |
Enrollment: | 39 |
Study Start Date: | May 2006 |
Study Completion Date: | July 2007 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, Ontario | |
Regional Mental Health Care London | |
London, Ontario, Canada, N6A 4H1 |
Principal Investigator: | Stewart B Harris, MD MPH CCFP FACPM | Centre for Studies in Family Medicine |
Principal Investigator: | David RS Haslam, MSc MD FRCPC | Regional Mental Health Care, London |
Study ID Numbers: | R-05-470 |
Study First Received: | September 14, 2006 |
Last Updated: | July 20, 2007 |
ClinicalTrials.gov Identifier: | NCT00377117 |
Health Authority: | Canada: Health Canada |
Schizophrenia Metabolic Diseases Mental Disorders Diabetes Mellitus Endocrine System Diseases |
Psychotic Disorders Endocrinopathy Metabolic disorder Glucose Metabolism Disorders Schizophrenia and Disorders with Psychotic Features |